Are there any contraindications for lurbinectedin combinations?

Who should avoid lurbinectedin combinations?

Individuals with a history of severe hypersensitivity reactions to lurbinectedin or its excipients should not receive combination treatments. Furthermore, lurbinectedin combinations are contraindicated in patients with severe hepatic impairment, as it may exacerbate liver function decline [1].

Hypersensitivity warnings

Pre-existing hypersensitivity reactions to lurbinectedin or its excipients can increase the risk of severe reactions, including anaphylaxis, when combination treatments are administered. Patients should be monitored closely for signs of hypersensitivity, and treatment discontinued if a severe reaction occurs [2].

Liver function considerations

Severe hepatic impairment can increase the risk of lurbinectedin combination treatments leading to further liver function decline. Dose adjustments may be necessary in patients with moderate hepatic impairment, and combination treatments should be avoided in those with severe hepatic impairment [3].

Pregnancy and breastfeeding warnings

The safety of lurbinectedin in pregnant and breastfeeding women has not been adequately established. However, animal studies have suggested potential fetal harm and maternal toxicity. Women of childbearing potential should use effective contraception during treatment, and those who become pregnant or breastfeeding should be counselled about the potential risks [4].

Other contraindications

Combination treatments with lurbinectedin are also contraindicated in patients with certain medical conditions, including severe bone marrow suppression, severe bleeding disorders, and other severe pre-existing medical conditions. Patients should undergo thorough medical evaluation prior to starting combination treatments [5].

References

[1] Clinicaltrials.gov: "Lurbinectedin Clinical Trials" (2022)
[2] Lurbinectedin Prescribing Information (Teva Pharmaceuticals, 2022)
[3] European Medicines Agency: "Assessment report for Xpovio" (2020)
[4] Food and Drug Administration: "Pregnancy and Lactation Labeling Rule (PLLR) Final Rule" (2015)
[5] Teva Pharmaceuticals: "Lurbinectedin Fact Sheet for Healthcare Providers" (2022)